TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33267558

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study: 34984539

Group type: EXPERIMENTAL
Intervention: GEN0101 (low dose: 30,000 mNAU)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GEN0101 (high dose: 60,000 mNAU)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GEN0101 (combined results)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GEN0101
Number of subjects: 6
Study: 33450656

Group type: EXPERIMENTAL
Intervention: Starch‐ and sucrose‐reduced diet (SSRD) for 4 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 105
Study: 32779197

Group type: EXPERIMENTAL
Intervention: Infant Motor Activity Log (IMAL) for children with impairments
Number of subjects: 66

Group type: COMPARATOR
Intervention: Infant Motor Activity Log (IMAL) for typically developing infants
Number of subjects: 66
Study: 35176134

Group type: EXPERIMENTAL
Intervention: Mini-dose glucagon (MDG)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral glucose tablets (OG)
Number of subjects: 17
Study: 32468649

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lemborexant (doses through 25 mg)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 32790051

Group type: EXPERIMENTAL
Intervention: Symptom-tracking app group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Calendar app group
Number of subjects: 91

Group type: COMPARATOR
Intervention: No app control group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: General symptom reporting across all groups
Number of subjects: 91
Study: 34888654

Group type: EXPERIMENTAL
Intervention: Pulse dexamethasone (3 mg/kg/day, max 100 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 32401981

Group type: EXPERIMENTAL
Intervention: Pcv‐aCO2/Ca‐cvO2 > 1.4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pcv‐aCO2/Ca‐cvO2
Number of subjects: 0
Study: 33807319

Group type: EXPERIMENTAL
Intervention: Reduced calorie diet provided by a whole-diet replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34981622

Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg once daily
Number of subjects: 3621

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3621
Study: 33459833

Group type: EXPERIMENTAL
Intervention: 6-week return to full weight bearing (WB)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 8-week return to full weight bearing (WB)
Number of subjects: 35
Study: 32590968

Group type: EXPERIMENTAL
Intervention: < 3 hours/week exercise
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Feeling not fit
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: VO2max distribution
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Levels of exercise, self-assessed fitness, and BMI
Number of subjects: 124
Study: 35334548

Group type: EXPERIMENTAL
Intervention: Specialized physical therapy with partial body weight supported treadmill training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Specialized physical therapy without partial body weight supported treadmill training
Number of subjects: 30
Study: 32692425

Group type: EXPERIMENTAL
Intervention: Cannabis use at age 14
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Tobacco use at age 14
Number of subjects: 583
Study: 32361773

Group type: EXPERIMENTAL
Intervention: Curcuma longa L. extract (CLE) 3 capsules per day, 500 mg each
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PLA) 3 capsules per day, 500 mg of microcrystalline cellulose
Number of subjects: 28
Study: 36451343

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 127

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab (in patients with brain metastasis)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Erlotinib (in patients with brain metastasis)
Number of subjects: 127
Study: 33268410

Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 347
Study: 35301941

Group type: EXPERIMENTAL
Intervention: eHealth hearing aid management education program
Number of subjects: 78

Group type: COMPARATOR
Intervention: treatment-as-usual (TAU)
Number of subjects: 78
Study: 34257152

Group type: EXPERIMENTAL
Intervention: Current HTP users
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Stealth use of HTPs
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Dual cigarette users (HTPs and electronic cigarettes)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Triple users (HTPs, ECs, and combustible cigarettes)
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Agreement with allowing indoor HTP use
Number of subjects: 7000
Study: 32275031

Group type: EXPERIMENTAL
Intervention: Topical administration of papaverine with left stellate ganglion blockade (LSGB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical administration of papaverine alone (Control Group-C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Left stellate ganglion blockade (LSGB)
Number of subjects: 100
Study: 34391687

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil application plus routine care
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (conventional diuretics, positive inotropic agents, and related therapy according to the guidelines)
Number of subjects: 147
Study: 34121734

Group type: EXPERIMENTAL
Intervention: Xylocaine + MgSO4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xylocaine
Number of subjects: 0
Study: 32379303

Group type: EXPERIMENTAL
Intervention: Intervention Group
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 329
Study: 33285548

Group type: EXPERIMENTAL
Intervention: Amine fluoride/sodium fluoride (12,500 ppm F; pH = 4.4; AmF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: NaF (12,500 ppm; pH = 6.6; NaF1)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: NaF (12,500 ppm; pH = 6.3; NaF2)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (14,200 ppm; pH = 8.7; SDF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride (12,500 ppm; pH = 3.8; APF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Highly fluoridated dentifrice (5,000 ppm)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard control (no intervention)
Number of subjects: 240
Study: 32331019

Group type: EXPERIMENTAL
Intervention: HP-3070 high-dose
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: HP-3070 low-dose
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 616
Study: 32847397

Group type: EXPERIMENTAL
Intervention: Device-guided slow breathing (DGB) for 8 weeks (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham device for 8 weeks (n = 13)
Number of subjects: 25
Study: 35272029

Group type: EXPERIMENTAL
Intervention: Corticosteroids + mesalamine (4 g/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Corticosteroids alone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Corticosteroids + mesalamine
Number of subjects: 149
Study: 32816563

Group type: EXPERIMENTAL
Intervention: Revised registration documents
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Changes in study characteristics
Number of subjects: 172

Group type: COMPARATOR
Intervention: Publications affected by revisions
Number of subjects: 172
Study: 32098767

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 247

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 247

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 247
Study: 35525414

Group type: EXPERIMENTAL
Intervention: Laparoscopic Anatomical Hepatectomy (LAH)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Laparoscopic Non-anatomical Hepatectomy (LNAH)
Number of subjects: 385
Study: 34120942

Group type: EXPERIMENTAL
Intervention: Physical exercise (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-physical exercise
Number of subjects: 0
Study: 34669036

Group type: EXPERIMENTAL
Intervention: Xbox Kinect group (VR training)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resistance exercise group
Number of subjects: 60
Study: 33287773

Group type: EXPERIMENTAL
Intervention: Anterolateral acromioplasty
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lateral acromioplasty
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Precise acromioplasty
Number of subjects: 60
Study: 35972832

Group type: EXPERIMENTAL
Intervention: Complex behavioural change intervention combining behaviour change communication and access to a habit formation mobile application
Number of subjects: 549

Group type: COMPARATOR
Intervention: Standard care provided by public health clinics in Malaysia
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Complex behavioural change intervention
Number of subjects: 549
Study: 34117592

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 32709005

Group type: EXPERIMENTAL
Intervention: Healthy Me one‐year program (multicomponent intervention using multimedia technologies)
Number of subjects: 1111
Study: 36094813

Group type: EXPERIMENTAL
Intervention: Standard 8-session web-based mindfulness-based cognitive therapy (MBCT)
Number of subjects: 4411

Group type: COMPARATOR
Intervention: Brief 3-session mindfulness training intervention
Number of subjects: 4411

Group type: COMPARATOR
Intervention: Comparison of MBCT vs brief mindfulness
Number of subjects: 4411
Study: 33596771

Group type: EXPERIMENTAL
Intervention: Increased cadence (CAD)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Forefoot strike (FFS)
Number of subjects: 33
Study: 33132302

Group type: EXPERIMENTAL
Intervention: New scoring system for predicting clinical severity and prognosis of COVID-19
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: New scoring system for predicting severe cases of COVID-19
Number of subjects: 444
Study: 36043918

Group type: EXPERIMENTAL
Intervention: STOP-BANG questionnaire
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Other difficult airway determinant tests
Number of subjects: 200
Study: 34165999

Group type: EXPERIMENTAL
Intervention: Mindfulness of Breath (MoB)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Mindfulness of Pain (MoP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Cognitive-Behavioral pain psychoeducation (CB)
Number of subjects: 118
Study: 32113994

Group type: EXPERIMENTAL
Intervention: Steroid therapy (dexamethasone 4 mg three times daily for 5 days)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 532
Study: 34543422

Group type: EXPERIMENTAL
Intervention: Training and tool kit (Arm 1)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training and tool kit plus referral system to CHW (Arm 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both Arm 1 and Arm 2
Number of subjects: 26
Study: 34205551

Group type: EXPERIMENTAL
Intervention: Daily physical activity text message reminders (Intervention Group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 32
Study: 35328968

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 91
Study: 33565825

Group type: EXPERIMENTAL
Intervention: Local administration of 80 mg of triamcinolone
Number of subjects: 60
Study: 32079920

Group type: EXPERIMENTAL
Intervention: ENCAP (maltodextrin, fructose, sodium alginate, and pectin)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: POLY (maltodextrin and fructose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: MON (glucose and fructose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ENCAP vs MON
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ENCAP vs POLY
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All drinks
Number of subjects: 8
Study: 35999237

Group type: COMPARATOR
Intervention: Care as usual during the control phase of the STARSHIP Trial
Number of subjects: 860
Study: 33812198

Group type: EXPERIMENTAL
Intervention: Participants with MS (contracture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 40
Study: 32843079

Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (1000 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral iron supplementation (100 mg ferrous fumarate with 60 mg ascorbic acid)
Number of subjects: 200
Study: 34694277

Group type: EXPERIMENTAL
Intervention: Single-dose metronidazole (2 g)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Multidose metronidazole (500 mg twice daily for 7 days)
Number of subjects: 540
Study: 33622506

Group type: EXPERIMENTAL
Intervention: CBM-I sessions via the HabitWorks app during acute care and postdischarge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HabitWorks app
Number of subjects: 0
Study: 34714120

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH (39.2 mg/7.8 mg/day, titrated to maximum dose of 52.3/10.4 mg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: SDX/d-MPH
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 33247645

Group type: EXPERIMENTAL
Intervention: Omalizumab biosimilar
Number of subjects: 105

Group type: COMPARATOR
Intervention: Reference product (Omalizumab)
Number of subjects: 105
Study: 36336666

Group type: EXPERIMENTAL
Intervention: PROERD intervention (10 classes taught by trained police officers)
Number of subjects: 4030

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4030
Study: 33592558

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 36442825

Group type: EXPERIMENTAL
Intervention: CRT-ON arm
Number of subjects: 353
Study: 33092632

Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma (CCP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 114
Study: 34839962

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training, 3 times a week for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group underwent multidisciplinary care for T2D
Number of subjects: 50
Study: 34529503

Group type: EXPERIMENTAL
Intervention: Respecting the Circle of Life program (RCL)
Number of subjects: 534
Study: 35135624

Group type: EXPERIMENTAL
Intervention: Public commitment charter
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-prescription pad
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 41
Study: 33839309

Group type: EXPERIMENTAL
Intervention: Laparoscopic excision of endometriotic foci and hysteroscopy with endometrial sampling
Number of subjects: 33

Group type: COMPARATOR
Intervention: Endometrial sampling from control group
Number of subjects: 33
Study: 35486015

Group type: EXPERIMENTAL
Intervention: Thunder-fire moxibustion combined with meibomian gland massage
Number of subjects: 72

Group type: COMPARATOR
Intervention: 0.1% fluo‐rometholone eye drops and 0.1% sodium hyaluronate eye drops, 1-2 drops per time, four times per day, and meibomian gland massage once per day
Number of subjects: 72
Study: 35613727

Group type: EXPERIMENTAL
Intervention: MVA at weeks 0/8 + LIPO‐5 at weeks 20/28 (M/L)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: LIPO‐5 at weeks 0/8 + MVA at weeks 20/28 (L/M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DNA at weeks 0/4/12 + LIPO‐5 at weeks 20/28 (G/L)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DNA at weeks 0/4/12 + MVA at weeks 20/28 (G/M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MVA-receiving groups (M/L, L/M, G/M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MVA-receiving groups (M/L, G/M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: MVA gene signature
Number of subjects: 92
Study: 33656972

Group type: EXPERIMENTAL
Intervention: Etoposide and sobuzoxane
Number of subjects: 0
Study: 32820733

Group type: EXPERIMENTAL
Intervention: Rotavirus positive samples
Number of subjects: 269
Study: 35172742

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making (SDM) perceived by General Practitioners (GPs)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Shared Decision-Making (SDM) perceived by patients
Number of subjects: 176

Group type: COMPARATOR
Intervention: Shared Decision-Making (SDM) perceived by external observers
Number of subjects: 176
Study: 33255249

Group type: EXPERIMENTAL
Intervention: Low glycemic index dietary intervention during pregnancy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 35802649

Group type: EXPERIMENTAL
Intervention: Targeted therapies (TT) including selumetinib, vistusertib, capivasertib, AZD4547, AZD8931, vandetanib, olaparib, savolitinib
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Durvalumab in patients with PD-L1 TPS ≥1%
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Durvalumab in patients with PD-L1 <1%
Number of subjects: 358
Study: 32628509

Group type: EXPERIMENTAL
Intervention: Phonomotor Therapy (PMT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Semantic Feature Analysis (SFA)
Number of subjects: 57
Study: 2010501984

Group type: EXPERIMENTAL
Intervention: Dermacyn
Number of subjects: 178

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 178
Study: 34542221

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study: 33568628

Group type: EXPERIMENTAL
Intervention: UC-MSCs (4×10^7 cells per infusion)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 34268829

Group type: EXPERIMENTAL
Intervention: Active participation in nursing handover
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Passive participation in nursing handover
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: No input in nursing handover
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Factors influencing active participation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Themes from interviews
Number of subjects: 33
Study: 33348282

Group type: EXPERIMENTAL
Intervention: Higher food prices
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Higher neighborhood poverty
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Policies and programs addressing food prices
Number of subjects: 3473
Study: 32511165

Group type: EXPERIMENTAL
Intervention: Welch Allyn SureSight
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Plusoptix PowerRefractor
Number of subjects: 21

Group type: COMPARATOR
Intervention: Grand Seiko WR‐5100K
Number of subjects: 21
Study: 35105533

Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Double antithrombotic therapy (DAT)
Number of subjects: 209
Study: 32311976

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Jianpi Yangzheng Xiaozheng decoction (JPYZXZ)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 210
Study: 36174930

Group type: EXPERIMENTAL
Intervention: 50mg losartan
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 33252090

Group type: EXPERIMENTAL
Intervention: Individualized semi-supervised home-based exercise program (3 times a week for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assistive training device
Number of subjects: 0
Study: 32979907

Group type: EXPERIMENTAL
Intervention: Topical atorvastatin 5% cream plus topical betamethasone 1% ointment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Topical betamethasone 1% ointment plus vehicle cream
Number of subjects: 88
Study: 34971258

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation virtual therapy (CSVT) program, 6 months, 2 sessions per week (N = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Active control group (N = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation virtual therapy (CSVT) program
Number of subjects: 20
Study: 32977212

Group type: EXPERIMENTAL
Intervention: Active multifocal tDCS (20 min, 1 mA per electrode, using 4 anodes and 4 cathodes)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 46
Study: 35687761

Group type: EXPERIMENTAL
Intervention: lacutamab (anti-KIR3DL2 humanized antibody)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: KIR3DL2 expression
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: HTLV-1 infection
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: KIR3DL2 and TAX mRNA expression levels
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: KIR3DL2 promoter demethylation
Number of subjects: 71
Study: 34132506

Group type: EXPERIMENTAL
Intervention: 3-0 polyglycolic acid sutures
Number of subjects: 62

Group type: COMPARATOR
Intervention: 3-0 black silk sutures
Number of subjects: 62
Study: 32432798

Group type: EXPERIMENTAL
Intervention: Tildrakizumab (IL-23p19 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35902155

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Number of subjects: 196
Study: 34931372

Group type: EXPERIMENTAL
Intervention: Hyzetimibe (HS‐25)
Number of subjects: 24
Study: 32502991

Group type: EXPERIMENTAL
Intervention: RECO Flow Restoration Device
Number of subjects: 136

Group type: COMPARATOR
Intervention: Solitaire FR
Number of subjects: 136
Study: 34427473

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa) 80 µg/kg intravenously over 2 min
Number of subjects: 860

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (rFVIIa)
Number of subjects: 860